Davies FE - Search Results

1

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA. Morgan GJ, et al. Among authors: davies fe. Leukemia. 2018 Nov;32(11):2435-2444. doi: 10.1038/s41375-018-0108-y. Epub 2018 Mar 23. Leukemia. 2018. PMID: 29654269 Free PMC article.

2

Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML.

Evans PA, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR, Davies F, Tobal K, Liu Yin JA, Morgan GJ. Evans PA, et al. Leukemia. 1997 Mar;11(3):364-9. doi: 10.1038/sj.leu.2400578. Leukemia. 1997. PMID: 9067575

3

p53 gene mutations in multiple myeloma.

Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. Owen RG, et al. Mol Pathol. 1997 Feb;50(1):18-20. doi: 10.1136/mp.50.1.18. Mol Pathol. 1997. PMID: 9208809 Free PMC article.

4

The use of biological variables to predict outcome in multiple myeloma.

Davies FE, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1997 Dec;99(4):719-25. Br J Haematol. 1997. PMID: 9432013 Free article. Review. No abstract available.

5

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1998 Jan;100(1):176-83. doi: 10.1046/j.1365-2141.1998.00525.x. Br J Haematol. 1998. PMID: 9450807 Free article.

6

True spectrum of 14q32 translocations in multiple myeloma.

Pratt G, Fenton JA, Proffitt JA, Rawstron AC, Davies FE, Child JA, Morgan GJ. Pratt G, et al. Among authors: davies fe. Br J Haematol. 1998 Dec;103(4):1209-10. doi: 10.1046/j.1365-2141.1998.1161d.x. Br J Haematol. 1998. PMID: 9886346 Free article. No abstract available.

7

Controversies surrounding the clonogenic origin of multiple myeloma.

Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Br J Haematol. 2000 Jul;110(1):240-1. doi: 10.1046/j.1365-2141.2000.02072-6.x. Br J Haematol. 2000. PMID: 10931011 Free article. No abstract available.

8

Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma.

Pratt G, Fenton JA, Davies FE, Rawstron AC, Richards SJ, Collins JE, Owen RG, Jack AS, Smith GM, Morgan GJ. Pratt G, et al. Among authors: davies fe. Br J Haematol. 2001 Feb;112(2):388-91. doi: 10.1046/j.1365-2141.2001.02588.x. Br J Haematol. 2001. PMID: 11167836 Free article.

9

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. Davies FE, et al. Blood. 2001 Jul 1;98(1):210-6. doi: 10.1182/blood.v98.1.210. Blood. 2001. PMID: 11418482 Free article.

10

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC. Podar K, et al. Among authors: davies fe. Blood. 2001 Jul 15;98(2):428-35. doi: 10.1182/blood.v98.2.428. Blood. 2001. PMID: 11435313 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

361 results

Search Page